Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic targeting of integrin αvβ6 in breast cancer.
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Moore KM, et al. Among authors: vallath s. J Natl Cancer Inst. 2014 Jun 28;106(8):dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 24974129 Free PMC article.
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Whilding LM, et al. Among authors: vallath s. Mol Ther. 2017 Jan 4;25(1):259-273. doi: 10.1016/j.ymthe.2016.10.012. Epub 2017 Jan 4. Mol Ther. 2017. PMID: 28129120 Free PMC article.
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.
Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF. Reader CS, et al. Among authors: vallath s. J Pathol. 2019 Nov;249(3):332-342. doi: 10.1002/path.5320. Epub 2019 Jul 30. J Pathol. 2019. PMID: 31259422 Free PMC article.
Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L, Vallath S, Gros A, Giménez-Alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M, Alemany R, Hart IR. Coughlan L, et al. Among authors: vallath s. Hum Gene Ther. 2012 Sep;23(9):960-79. doi: 10.1089/hum.2011.218. Epub 2012 Aug 27. Hum Gene Ther. 2012. PMID: 22708837 Clinical Trial.
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Whilding LM, Parente-Pereira AC, Zabinski T, Davies DM, Petrovic RMG, Kao YV, Saxena SA, Romain A, Costa-Guerra JA, Violette S, Itamochi H, Ghaem-Maghami S, Vallath S, Marshall JF, Maher J. Whilding LM, et al. Among authors: vallath s. Mol Ther. 2017 Oct 4;25(10):2427. doi: 10.1016/j.ymthe.2017.09.018. Epub 2017 Sep 23. Mol Ther. 2017. PMID: 28958577 Free PMC article. No abstract available.
24 results